An interventional study of Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention and Pulmonary Vascular Interventional Therapy in Fibrosing Mediastinitis and Pulmonary Hypertension, sponsored by Beijing Chao Yang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Beijing Chao Yang Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.
Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 38th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 with no phase, reaches primary completion later than 21 of the 35 other live ones, and was the 72nd registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Xiamen Cardiovascular Hospital, Xiamen University · Sites in China
Ages 18–80
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 100 across the 47 interventional studies, 750 across the 36 observational. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 85 have an industry lead sponsor. The 10 most frequent:
Beijing Chao Yang Hospital is the lead sponsor of 142 studies on the registry; 51 are open to participants now.
Beijing Chao Yang Hospital has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension, Pulmonary with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT06023134Jingyi RenClinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure | 2027-09-01 |
| NCT06980584Beijing Chao Yang HospitalStudy on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Hypertension, Pulmonary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group will receive both pulmonary vascular intervention and rituximab lymph node injection.
Procedure: Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention
Participants assigned to this group will receive pulmonary vascular intervention alone.
Procedure: Pulmonary Vascular Interventional Therapy
Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.
Change from Baseline in the Six Minutes Walk Distance at 12 Months.
Conduct 6-minute walk test to measure the 6-minute walk distance, and compare the walking distances at baseline and 12 months after treatment.
Time frame: From enrollment to the end of treatment at 12 months
The incidence of treatment-related serious adverse events (SAE)
The incidence of treatment-related serious adverse events is measured by tracking and documenting any SAEs that occur during the treatment period, as well as through follow-up assessments. Each event is evaluated for severity and causality, and the incidence is calculated by dividing the number of patients who experience at least one treatment-related SAE by the total number of treated patients.
Time frame: During the one-year follow-up period after treatment completion
Change from baseline in the World Health Organization Functional Classification of Pulmonary Hypertension at 3, 6 and 12 months.
Change from Baseline in the World Health Organization Functional Classification of Pulmonary Hypertension (WHO-FC) which assessed based on clinical symptoms and signs at baseline and the end of treatment at 3, 6 and 12 months. The WHO-FC system consists of four levels: I, II, III, and IV. Higher levels indicate progressively more severe conditions.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months.
Change from Baseline in the mean pulmonary artery pressure (mPAP) at 3 and 12 Months.
The mean pulmonary artery pressure (mPAP) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.
Time frame: From enrollment to the end of treatment at 3 and12 months
Change from Baseline in the Cardiac Index (CI) at 3 and 12 Months.
The Cardiac Index (CI) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.
Time frame: From enrollment to the end of treatment at 3 and12 months
Change from Baseline in the Pulmonary Vascular Resistance (PVR) at 3 and 12 Months.
The Pulmonary Vascular Resistance (PVR) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.
Time frame: From enrollment to the end of treatment at 3 and12 months
Change from Baseline in the forced vital capacity (FVC) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced vital capacity (FVC), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the forced vital capacity of predicted (FVC%pred) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced vital capacity of predicted (FVC%pred), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the forced expiratory volume in 1 second (FEV1) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced expiratory volume in 1 second (FEV1), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the forced expiratory volume in 1 second of predicted (FEV1%pred) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced expiratory volume in 1 second of predicted (FEV1%pred), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the FEV1/FVC ratio at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the FEV1/FVC ratio, to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change of the BNP/NT-Pro BNP from baseline to the end of treatment at 3, 6 and 12 months.
The BNP/NT-Pro BNP will be measured at baseline the end of treatment at 3, 6 and 12 months to evaluate the condition of heart failure.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months.
The restenosis rate of blood vessels after interventional therapy at the end of treatment at 3 and 12 months
Restenosis following interventional therapy was monitored at the end of treatment at 3 and 12 months, with restenosis defined as a blood vessel diameter reduction of more than 50% from the original size, or when the pressure gradient (Pd) at the site of vascular stenosis increases by 5 mmHg or more compared to the last measurement.
Time frame: From enrollment to the end of treatment at 3 and 12 months.
Change of the mediastinal lesion volume from baseline to 3 and 12 months after the end of treatment.
The mediastinal lesion volume will be measured at baseline and 3, 12 months after the end of treatment using CTPA or PET-CT imaging. The volume is represented by the maximum transverse diameter of the cross-section of the lesion site.
Time frame: From enrollment to the end of treatment at 3 and12 months.
Change from baseline of the quality-of-life score at 3, 6 and 12 months after the end of treatment.
Quality of life was assessed using the 36-Item Short-Form Health Survey (SF-36) at baseline and 3, 6 and 12 months after the end of treatment. The SF-36 scoring scale consists of 8 dimensions, which can be summarized as physical health and mental health. The score range of each dimension is 0 to 100 points. The higher the score, the better the health condition.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Number of participants with complications of bronchoscopy and pulmonary intervention.
Measure the probability of complications occurring during or after therapeutic operations. Complications of pulmonary vascular intervention include pulmonary vascular injury, arrhythmia, reperfusion pulmonary edema, etc; Complications of bronchoscopy include pneumothorax, massive hemoptysis, infection, etc.
Time frame: Immediately or in the short term after treatment, and within 12 months after treatment
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Oct 2027, 32 months after the start.
Of 135 non-industry interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's planned 32 months is above that.
Counting every sponsor, half of 150 studies reached it within 23 months; a quarter within 9 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.